VivoSeq
Oncology

Neuroendocrine Cancer

0

Pipeline Programs↗

5

Active Trials↗

1

Companies Involved↗

Neuroendocrine Cancer is an early-stage landscape with 0 programs across 1 company. The most active players are Novartis.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

83/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

12

clinical trials

Completed5 · 42%
Active, not recruiting4 · 33%
Recruiting1 · 8%
Unknown status1 · 8%
Withdrawn1 · 8%

Clinical Trials

Trial Activity

12 trials

An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer
Recruiting·UUniversity of Michigan Rogel Cancer Center·Phase 1·NCT07132645·30 enrolled
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
Active, not recruiting·JJonsson Comprehensive Cancer Center·Phase 1·NCT03582475·15 enrolled
A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung
Active, not recruiting·TTechnische Universität Dresden·Phase 2·NCT05470595·67 enrolled
Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT04394858·46 enrolled
Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers
Active, not recruiting·National Cancer Institute (NCI)·Phase 1/2·NCT04802174·37 enrolled
Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy
Completed·Novartis logoNovartis·Phase 2·NCT00363051·160 enrolled
Capecitabine and Temozolomide for Neuroendocrine Cancers
Completed·—·Phase 2·NCT00869050·41 enrolled
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Completed·SSCRI Development Innovations, LLC·Phase 2·NCT02318784·62 enrolled
Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
Completed·National Cancer Institute (NCI)·Phase 2·NCT00454363·52 enrolled
Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers
Completed·SSCRI Development Innovations, LLC·Phase 2·NCT01121939·43 enrolled
Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine Cancers
Withdrawn·UUniversity of Alabama at Birmingham·Phase 1·NCT03623984
Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer
Unknown status·UUniversity of Warmia and Mazury·Phase 2·NCT04194125·25 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)